AIP
ZYNE

Ahrens Investment Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Ahrens Investment Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$447 Buy
+1,040
New +$548 ﹤0.01% 970
2022
Q3 		– Sell
-1,040
Closed -$1K – 980
2022
Q2 		$1K Hold
1,040
– – ﹤0.01% 952
2022
Q1 		$2K Hold
1,040
– – ﹤0.01% 970
2021
Q4 		$3K Buy
+1,040
New +$3.85K ﹤0.01% 953

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ahrens Investment Partners's ZYNE Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023: 1,040 shares worth $447. The stake represents ﹤0.01% of the portfolio and ranks #970 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in ZYNE as recently as Q2 2022.

Ahrens Investment Partners first reported a position in ZYNE in Q4 2021 and has held it in 4 quarters since. The position peaked at $3K in Q4 2021. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Ahrens Investment Partners held 1,040 shares of Zynerba Pharmaceuticals, Inc worth $447 as of Q1 2023.
  • Zynerba Pharmaceuticals, Inc was a new Ahrens Investment Partners position in Q1 2023.
  • Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #970 holding.
  • Ahrens Investment Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2021 and has held it in 4 quarters since.
  • Ahrens Investment Partners's Zynerba Pharmaceuticals, Inc position peaked at $3K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.